Description: Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases. It engages in the research and development of therapies for the treatment of type 1 diabetes in children, and multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.
Home Page: poltreg.tech
Waly Piastowskie 1 lok. 1508
Gdansk,
80-855
Poland
Phone:
48 512 53 24 01
Officers
| Name | Title |
|---|---|
| Mr. Piotr Trzonkowsk | Pres of the Management Board |
| Ms. Kamilla Agnieszka Bok | Member of the Management Board & Director of Operations |
| Mr. Mariusz Jablonski | Member of the Management Board |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0856 |
| Price-to-Sales TTM: | 178.9147 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |